Changed accounting treatment regarding contract production of wound care products

Coloplast has renewed a five-year contract production agreement for Compeed
products. Under the terms of the new contract, this business will be recognised
line by line in the income statement, whereas the activity was previously
recognised as a net amount under “Other income”. The change will increase wound
and skin care revenue by about DKK 160m, while EBIT is unaffected. The revenue
increase will not be recognised in organic growth, as it is purely the result
of a change in accounting treatment - see enclosed PDF.